GlassScriptPhysician profile
Rosilin Joseph
NPI 1275112153
$1,356.70
in general payments reported to CMS, 2019-2025
12 companies · $558 in 2025
The $558 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $799 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.47 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $140.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $115.68 | 2023 | Soliris |
| Xeris Pharmaceuticals, INC. | $113.37 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $109.94 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $109.84 | 2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $103.32 | 2023 | Terlivaz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2025 | |
| Biogen, INC. | $97.98 | 2023 | |
| Insmed, INC. | $97.67 | 2025 | Arikayce |
| Sanofi-Aventis U.S. LLC | $70.00 | 2023 | |
| Dexcom, INC. | $21.43 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosilin Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.